Noga Harizman is an Ophthalmology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 60 publications with 1,104 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
310 E 14th St
Suite 319 South
New York, NY 100034201
Telephone
212-979-4503Registry record last updated 18 Dec 2012.
Clinical trials
- The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
Sponsor: The New York Eye & Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20253 payments
- ABBVIE INC.Program year20252 payments
- Glaukos CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
90.9%Prostaglandin Analog39.8%Latanoprost73%Lumigan18%Travoprost6%Tafluprost2%Part D<11 patientsCarbonic Anhydrase Inhibitor25.4%Dorzolamide-Timolol58%Dorzolamide Hcl18%Brinzolamide15%Simbrinza7%Cosopt Pf2%Part D<11 patients+ 6 more classes in this area
Cardiovascular
6.2%Beta blocker6.2%Timolol Maleate100%Part D≥54 patientsNervous system
1.8%Cholinergic Receptor Agonist1.8%Pilocarpine Hcl100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patient Navigators Improve In-Office Eye Exam Adherence After Community Eye Screenings in a Randomized Clinical Trial: NYC-SIGHT Study
American Journal of Ophthalmology
2025 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT): optometric exam improves access and utilization of eye care services
Graefe s Archive for Clinical and Experimental Ophthalmology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Clerkin, MD
NewYork–Presbyterian Hospital
Brandon Swed, MD
NewYork–Presbyterian Hospital
Lawrence Lenke, MD
NewYork–Presbyterian Hospital
Manuel Hidalgo Medina, MD
NewYork–Presbyterian Hospital
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”